RxDoctor Payments Data

David Kay, MD

General Practice · Hamilton, GANPI 1720057102

Payments from drug & device makers

$934in general payments, 2019–2025

Across 30 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$386
  • Lilly USA, LLC$173
  • Novo Nordisk$108
  • Lucid Diagnostics Inc.$97
  • Boehringer Ingelheim$97
  • Paratek Pharmaceuticals, Inc.$24
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$934 in reported general payments places this provider in the 75th percentile of 2,542 general practice providers in Georgia.

See all general practice providers in Georgia

Medicare billing

Part B allowed, 2024
$37,738
Medicare patients
163
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol146$105,924
OzempicSemaglutide30$35,019
JardianceEmpagliflozin37$28,775
EliquisApixaban38$26,377
RybelsusSemaglutide28$26,369
MounjaroTirzepatide15$15,958
XareltoRivaroxaban15$13,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,432
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,120
LinzessLinaclotide12$7,118
TradjentaLinagliptin12$6,300
PremarinEstrogens, Conjugated15$4,717
Atrovent HfaIpratropium Bromide11$4,592
VascepaIcosapent Ethyl13$4,369
Albuterol Sulfate HfaAlbuterol Sulfate85$2,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$386$114,044159 claims
Novo NordiskOzempic, Rybelsus$108$61,38858 claims
Boehringer IngelheimJardiance, Tradjenta$97$35,07449 claims
Lilly USA, LLCMounjaro$173$15,95815 claims
AbbVieLinzess$18$7,11812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,542 general practice providers in Georgia.

Other general practice in Hamilton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →